

Date Completed: _____

Immuno-Oncology Care Transition Summary

TREATMENT SUMMARY	
Name of Patient: _____	
Oncologist: _____	Contact Info: _____

DIAGNOSIS	
Cancer Type/Location/Pathology: Ex. Poorly differentiated carcinoma of the left breast; Ki-67 of 30%	Diagnosis Date: _____
	Stage: <input type="checkbox"/> I <input type="checkbox"/> II <input type="checkbox"/> III <input type="checkbox"/> IV <input type="checkbox"/> Not applicable

TREATMENT		
Surgery: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, surgical procedure/location/findings:	Surgery Date: _____	
Radiation: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, radiation procedure/location:	Initiation Date: _____	
Completed Date: _____		
Systemic Therapy (chemotherapy, targeted therapy, immunotherapy, other): <input type="checkbox"/> Yes <input type="checkbox"/> No		
Names of Agent(s) Used	Completed Date: (n/a, if ongoing)	Side Effects Experienced
•		
•		
•		
•		

Clinical Trial? <input type="checkbox"/> Yes <input type="checkbox"/> No	Initiation and Completion Dates: (If treatment is ongoing, choose "Current") Initiation: _____ Completion: _____ <input type="checkbox"/> Current
Clinical Trial Information: (Name/# of trial, expected f/u, study-specific contact names/numbers, etc.)	
Persistent Symptoms or Side Effects <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, explain below, including current management strategy and/or recommendations	
Symptom/Side Effect	Strategy/Recommendation
• Ex., pain from bone metastases	• Ex., Continue steroidal treatment and radiation.
•	•
•	•
•	•

Need for Ongoing (Maintenance) Treatment for Cancer <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown If yes, answer below:	
Agent	Start Date
•	_____
•	_____

SIDE EFFECT MONITORING

While most side effects from immunotherapy present within a few months, some may not present for up to several years after treatment discontinuation. In addition, some symptoms may appear to be connected to a different treatment or condition, while they may actually be serious side effects from immunotherapy.

Possible side effects for immunotherapy include: *

- | | |
|---|--|
| <ul style="list-style-type: none"> • Gastrointestinal: Diarrhea, colitis, acute pancreatitis • Pneumonitis: Inflammation in the lungs • Dermatologic: Rashes and itchiness • Endocrine: Diabetes, thyroid | <ul style="list-style-type: none"> • Musculoskeletal: Arthralgia, arthritis • Cardiovascular: Pericarditis, myocarditis, arrhythmia • Kidney infections |
|---|--|

**This is only a partial list. See guidelines below for definitive list.*

Notify the oncology care team if any new signs or symptoms develop, including severe fatigue, headache, rash, cough, shortness of breath, chest pain, abdominal bloating, change in bowel pattern, weight loss, vision changes or eye pain, severe muscle weakness, severe muscle or joint pains, and/or mood changes.

GUIDELINES FOR MANAGING IMMUNOTHERAPY SIDE EFFECTS

NCCN Clinical Guidelines

[nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf)

ESMO Clinical Practice Guidelines: Management of Toxicities From Immunotherapy

[esmo.org/content/download/151567/2718664/1/Clinical-Practice-Guidelines-Slideset-Toxicities-Immunotherapy.pdf](https://www.esmo.org/content/download/151567/2718664/1/Clinical-Practice-Guidelines-Slideset-Toxicities-Immunotherapy.pdf)

American Cancer Society Patient Education: Immune Checkpoint Inhibitors and Their Side Effects

[cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html](https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html)

NCCN Understanding Immunotherapy Side Effects

[nccn.org/images/pdf/Immunotherapy_Infographic.pdf](https://www.nccn.org/images/pdf/Immunotherapy_Infographic.pdf)

ADDITIONAL COMMENTS ABOUT PATIENT EXPERIENCE

(Specific notes about patient experience)

ADDITIONAL RESOURCES

Guidelines for Managing IO-Related Side Effects

acc-cancer.org/home/learn/resource-detail/irae-workup-guidelines

IO Wallet Card for Patients

acc-cancer.org/home/learn/immunotherapy/resource-detail/publication-io-wallet-card

The ACCC Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for cancer care teams across all healthcare settings. Access survivorship resources for patients on cancer immunotherapies at acc-cancer.org/home/learn/immunotherapy/survivorship.

© 2021. Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.